Short answer
PALVELLA THERAPEUTICS, INC. (PVLA) filed an 8-K current report with the SEC on June 16, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 5.07 (Submission of Matters to a Vote of Security Holders). Stockholders approved 750,000 additional shares under Palvella’s 2024 Equity Incentive Plan.
PALVELLA THERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Stockholders approved 750,000 additional shares under Palvella’s 2024 Equity Incentive Plan
- Effective immediately on June 10, 2026, expanding equity capacity for employee and executive compensation
- Potential dilution for existing shareholders as newly authorized awards may increase shares outstanding over time
Item 5.07 · Submission of Matters to a Vote of Security Holders
- 14,323,686 shares entitled to vote; Class III directors Jenkins, Davis, and Doux elected through 2029
- Ernst & Young LLP ratified as independent auditor for fiscal 2026, with 11,557,687 votes for
- Executive compensation approved advisory, with 10,008,180 votes for
- Annual say-on-pay frequency selected, establishing yearly advisory votes until the next required frequency vote
- Equity plan expanded by 750,000 shares, increasing potential dilution capacity; approved 7,692,709 to 2,475,470
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other PALVELLA THERAPEUTICS, INC. 8-K filings
Get the next PVLA 8-K as it lands
Follow PVLA for push alerts, or ask the research agent what this filing means.